Royal Bank of Canada Decreases Position in Perrigo Company plc $PRGO

Royal Bank of Canada trimmed its holdings in Perrigo Company plc (NYSE:PRGO) by 73.1% in the first quarter, HoldingsChannel.com reports. The firm owned 53,873 shares of the company’s stock after selling 146,044 shares during the quarter. Royal Bank of Canada’s holdings in Perrigo were worth $578,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in PRGO. Vanguard Group Inc. grew its position in shares of Perrigo by 7.9% in the 4th quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock valued at $208,568,000 after buying an additional 1,101,154 shares during the last quarter. Thompson Siegel & Walmsley LLC lifted its position in Perrigo by 28.4% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 4,658,601 shares of the company’s stock valued at $64,848,000 after acquiring an additional 1,029,770 shares during the last quarter. Gamco Investors INC. ET AL lifted its position in Perrigo by 29.7% in the first quarter. Gamco Investors INC. ET AL now owns 1,397,866 shares of the company’s stock valued at $15,013,000 after acquiring an additional 320,081 shares during the last quarter. Empowered Funds LLC boosted its stake in Perrigo by 41.6% in the first quarter. Empowered Funds LLC now owns 511,872 shares of the company’s stock valued at $5,498,000 after acquiring an additional 150,438 shares in the last quarter. Finally, Gabelli Funds LLC boosted its stake in Perrigo by 29.8% in the first quarter. Gabelli Funds LLC now owns 893,359 shares of the company’s stock valued at $9,595,000 after acquiring an additional 205,311 shares in the last quarter. 95.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on PRGO shares. Weiss Ratings upgraded Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a research report on Thursday, August 6th. Wall Street Zen raised Perrigo from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $19.33.

Perrigo Stock Up 0.0%

Shares of NYSE:PRGO opened at $14.25 on Tuesday. The stock has a market cap of $1.98 billion, a P/E ratio of -1.14, a P/E/G ratio of 1.62 and a beta of 0.51. The firm has a fifty day moving average price of $11.15 and a 200 day moving average price of $11.42. The company has a debt-to-equity ratio of 1.31, a current ratio of 2.32 and a quick ratio of 1.32. Perrigo Company plc has a 1-year low of $9.23 and a 1-year high of $24.49.

Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.11. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period last year, the firm posted ($0.06) EPS. Perrigo’s revenue for the quarter was down 3.1% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Sell-side analysts predict that Perrigo Company plc will post 2.2 EPS for the current year.

Perrigo Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 28th will be given a $0.29 dividend. This represents a $1.16 annualized dividend and a yield of 8.1%. The ex-dividend date is Friday, August 28th. Perrigo’s payout ratio is -9.27%.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.